For US healthcare professionals only

Important Safety Information | Prescribing Information | Patient Support | Celltrion USA | Patient Site

For US healthcare professionals only

Prescribing Information

Long-term remission from your hands to theirs

By Week 54, 43% of patients with UC and 63% with CD maintained clinical remission

(21% and 30% for placebo, respectively.)1

ZYMFENTRA™ is the first and only subcutaneous formulation of infliximab—indicated in adults for the maintenance treatment of moderate to severe UC or moderate to severe CD following an IV infliximab product.1,2

Explore the importance of steady and elevated serum drug levels.

See the PK Difference

Streamlined treatment process

ZYMFENTRA gives patients increased flexibility and convenience through self-administration—for more freedom with less restraints.

Clinical benefits in UC and CD

Ulcerative Colitis Chart

Ulcerative colitis

Crohn's Disease Chart

Crohn’s disease

Safety profile

See the safety profile for ZYMFENTRA, including common adverse reactions.1

  • No significant, meaningful difference was seen in the overall safety profile between ZYMFENTRA 120 mg and placebo
  • No new safety signals were identified during treatment with ZYMFENTRA
See Safety Data

Safety profile

See the safety profile for ZYMFENTRA, including common adverse reactions.1

  • No significant, meaningful difference was seen in the overall safety profile between ZYMFENTRA 120 mg and placebo
  • No new safety signals were identified during treatment with ZYMFENTRA
See Safety Data

Safety profile

See the safety profile for ZYMFENTRA, including common adverse reactions.1

  • No significant, meaningful difference was seen in the overall safety profile between ZYMFENTRA 120 mg and placebo
  • No new safety signals were identified during treatment with ZYMFENTRA
See Safety Data

Resources for you and your patients

Access prescription and enrollment forms as well as patient support tools and other resources.

Find Resources

CD=Crohn’s disease; IV=intravenous; PK=pharmacokinetics; UC=ulcerative colitis.

References: 1. ZYMFENTRA™ Prescribing Information, Celltrion, Inc., 2023. Celltrion USA, Inc. 2. Data on file. Celltrion, Inc.

Important Safety Information

WARNING: SERIOUS INFECTIONS and MALIGNANCY

Contraindications

Warnings and Precautions

Common Adverse Reactions (≥3%)

Drug Interactions

For more information, see full Prescribing Information including BOXED WARNING.